IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models [Yahoo! Finance]
Immuneering Corporation - Class A (IMRX)
Company Research
Source: Yahoo! Finance
yielded deeper and more durable tumor growth inhibition than either treatment alone - - Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting - - Immuneering expects initial data from multiple IMM-1-104 Phase 2a arms in 2024 - CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors. “Combination therapy is an important way to reduce therapeutic resistance, and we believe the emergent activity a
Show less
Read more
Impact Snapshot
Event Time:
IMRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRX alerts
High impacting Immuneering Corporation - Class A news events
Weekly update
A roundup of the hottest topics
IMRX
News
- Immuneering Co. (NASDAQ: IMRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $15.00 price target on the stock.MarketBeat
- IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsGlobeNewswire
- Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewswire
- Immuneering Co. (NASDAQ: IMRX) had its price target lowered by analysts at Mizuho from $20.00 to $8.00. They now have a "buy" rating on the stock.MarketBeat
- Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations [Yahoo! Finance]Yahoo! Finance
IMRX
Earnings
- 3/1/24 - Miss
IMRX
Sec Filings
- 4/23/24 - Form DEFA14A
- 4/23/24 - Form DEF
- 4/15/24 - Form SC
- IMRX's page on the SEC website